Japan’s Astellas Pharma Inc reiterated its full–year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug drug countered overseas acquisition costs.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
